argenx

argenx EBIT

The EBIT of argenx (ARGX.BR) as of Nov 17, 2026 is 1.18 B USD. In the previous year, EBIT was -24.22 M USD — a change of -4,970.30% (higher).

EBIT

1.18 BUSD

YoY

-4,970.30%

Last updated:

In 2025, argenx's EBIT was 1.18 B USD, a -4,970.30% increase from the -24.22 M USD EBIT recorded in the previous year.

The argenx EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT
Date
EBIT
Jan 1, 2023
-475.49 M USD
Jan 1, 2024
-24.22 M USD
Jan 1, 2025
1.18 B USD
Jan 1, 2026 (e)
2.41 B USD
Jan 1, 2027 (e)
3.32 B USD
Jan 1, 2028 (e)
4.21 B USD
Jan 1, 2029 (e)
5.26 B USD
Jan 1, 2030 (e)
6.18 B USD
The argenx EBIT history
YEAREBITYoY
est6.18 BUSD+17.36%
est5.26 BUSD+24.93%
est4.21 BUSD+27.04%
est3.32 BUSD+37.81%
est2.41 BUSD+103.91%
1.18 BUSD-4,970.30%
-24.22 MUSD-94.91%
-475.49 MUSD-40.99%
-805.82 MUSD+106.55%
-390.13 MUSD-26.98%
-534.30 MUSD+140.14%
-222.49 MUSD+112.43%
-104.74 MUSD+240.31%
-30.78 MUSD+22.15%
-25.20 MUSD+32.01%
-19.09 MUSD+30.60%
-14.61 MUSD+48.34%
-9.85 MUSD-33.75%
-14.87 MUSD+181.75%
-5.28 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

argenx Revenue

argenx Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2023
1.37 B USD
-475.49 M USD
-330.07 M USD
Jan 1, 2024
2.45 B USD
-24.22 M USD
931.90 M USD
Jan 1, 2025
4.65 B USD
1.18 B USD
1.45 B USD
Jan 1, 2026 (e)
6.74 B USD
2.41 B USD
1.90 B USD
Jan 1, 2027 (e)
8.54 B USD
3.32 B USD
2.62 B USD
Jan 1, 2028 (e)
10.05 B USD
4.21 B USD
3.33 B USD
Jan 1, 2029 (e)
11.59 B USD
5.26 B USD
4.15 B USD
Jan 1, 2030 (e)
13.25 B USD
6.18 B USD
4.88 B USD

argenx Margins

argenx stock margins

The argenx margin analysis displays the gross margin, EBIT margin, as well as the profit margin of argenx. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for argenx.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2023
90.39 %
-34.66 %
-24.06 %
Jan 1, 2024
89.62 %
-0.99 %
38.03 %
Jan 1, 2025
89.15 %
25.39 %
31.11 %
Jan 1, 2026 (e)
89.15 %
35.71 %
28.18 %
Jan 1, 2027 (e)
89.15 %
38.83 %
30.65 %
Jan 1, 2028 (e)
89.15 %
41.89 %
33.07 %
Jan 1, 2029 (e)
89.15 %
45.42 %
35.86 %
Jan 1, 2030 (e)
89.15 %
46.59 %
36.79 %

argenx Stock analysis

What does argenx do? Argenx SE is a biopharmaceutical company dedicated to the development of novel therapeutics for the treatment of serious diseases. The company was founded in 2008 and is headquartered in Gent, Belgium. Argenx utilizes an innovative technology platform, the Simple Antibody platform, to develop customized antibodies with high efficacy. Argenx operates in two main business areas: clinical development and licensing. The company aims to produce outstanding therapeutic agents from each of its platform technologies and drug candidates, which can be used as antibody therapies against serious autoimmune diseases or cancer. Argenx's main product is the drug Efgartigimod, a monoclonal antibody developed for the treatment of multiple autoimmune diseases, particularly generalized Myasthenia Gravis (GMG). The drug is currently in clinical development. In recent years, Argenx has made significant progress in the development of new drugs. For example, the company has announced the discovery of new antibodies for the treatment of Myasthenia Gravis, rheumatoid arthritis, and various types of cancer. Licensing these development pipelines opens up new opportunities for Argenx to create additional therapy options for patients with serious illnesses. Argenx has also established partnerships with leading pharmaceutical companies such as Shire and AbbVie to expand its technology platform and drug candidates into new areas of application. The company is currently working on the development of therapies for rare and serious diseases that have no satisfactory treatment options. With the advancement of its innovative technology platform and the expansion of its portfolio of drug candidates, Argenx is on a promising path to play a leading role in the industry. The company is building an extensive network of partnerships and collaborations to accelerate the further development of its technology platform and products, and to achieve further success in the search for new therapeutic applications and areas of application. Looking ahead, Argenx is poised to play a significant role in the biopharmaceutical industry, particularly in the development of personalized therapy options for the treatment of serious diseases where no satisfactory treatment options currently exist. Argenx is proud of its dedicated team of employees who strive every day to realize the company's vision - to help patients cope with serious illnesses through new and innovative therapies. Output: Argenx SE is a biopharmaceutical company dedicated to the development of novel therapeutics for the treatment of serious diseases. argenx is one of the most popular companies on Eulerpool.

EBIT Details

Analyzing argenx's EBIT

argenx's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of argenx's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

argenx's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in argenx’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about argenx stock

EBIT of argenx is 1.18 B USD in 2025.

EBIT of argenx changed from -24.22 M USD to 1.18 B USD, representing a -4,970.30% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBIT argenx since 2006 – with annual values, charts, and detailed analysis.

"Earnings before interest and taxes", abbreviated as EBIT, is also referred to as the operating result of a company. It is a key figure that allows the profit to be assessed over a specific period of time, usually a fiscal year. Taxes and interest are not deducted from EBIT, making it suitable for international comparisons of different companies.

Net income
+ Tax expense
+ Interest expense and other financial expenses
- Interest income and other financial income
= EBIT (operating profit)

EBIT's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT's argenx historically and in real time.

The sales revenue is important for evaluating a stock.

EBIT is an acronym for "Earnings Before Interest and Tax" and represents a company's gross profit before taxes and interest are deducted. The EBIT amount is often used as a metric to evaluate a company.

History

The EBIT was originally introduced in the 1940s when the US Internal Revenue Service (IRS) passed a new tax law. This law required companies to calculate their profit before deducting taxes and interest on loans (or "interest and taxes"). Since then, the EBIT has been used as one of the key financial indicators in evaluating a company.

Usage

The EBIT can be used to assess a company by comparing its financial results to a benchmark or a comparative value. The EBIT is also used to determine how much the company's shareholders will receive from its operating income.

Calculation

EBIT is calculated by deducting taxes and interest on loans from the company's net profit. This amount can be calculated in various ways, but the most common method is as follows:

EBIT = Net profit + interest and taxes

Example: Eulerpool: Your source for quantitative stock data At Eulerpool, we are dedicated to providing you with comprehensive and accurate stock information. Our website offers a wide range of tools and features, including charts, stock lists, and more. Whether you are an experienced investor or just starting out, our platform is designed to meet your needs. With our in-depth analytics and algorithms, you can make informed decisions and stay ahead of the market. Explore our extensive collection of stocks, track their performance, and access real-time data. With Eulerpool, you can easily navigate the world of finance and monitor the stocks that matter to you. Join our community today and gain valuable insights into the world of stocks and investments. Sign up for free and discover the power of Eulerpool. Stay informed. Stay ahead. Eulerpool - your trusted partner in stock data.
Net profit of XYZ Co. = $1,000,000
Interest and taxes = $ 500,000
EBIT of XYZ Co. = $1,500,000

Application

The EBIT value is often used to determine and evaluate the financial stability of a company. The EBIT value can also be used to determine how much money a company can spend on investments or dividends.

Use of EBIT in stock investment

Investors use EBIT to determine if a stock is over- or undervalued. If a company has a high EBIT value, it may indicate that its stock is overvalued, as the profit it generates could be lower than what it would generate with a different stock.

Advantages of EBIT

EBIT is a helpful measure for determining the financial stability of a company. There are several advantages associated with using EBIT, such as:
- EBIT eliminates the impact of financing on the company's earnings.
- It is a useful measure for determining the profits that a company can distribute to its shareholders.
- It can be used to determine whether a stock is overvalued or undervalued.

Disadvantages of EBIT

There are also some disadvantages to using EBIT, such as:
- EBIT cannot be used as the sole measure to evaluate a company as it does not reflect the overall profit of the company.
- EBIT can be influenced by unforeseen events such as a tax increase.
- EBIT is not always a reliable indicator of a company's future profit development.

Conclusion

The EBIT is an important measure used to evaluate a company. It can be used to determine how much money a company can generate from its operational results and whether a stock is overvalued or undervalued. However, the EBIT also has some disadvantages as it does not reflect the overall profitability of a company and can be influenced by unforeseen events. Therefore, it is important to consider the EBIT in conjunction with other financial indicators to obtain a complete picture of the company.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — argenx

All Key Metrics — argenx